1. Dai W, Luo B, Wu Z, Chen J, Feng G, Guan P. A multi-center phase II study of nintedanib
as second-line therapy for patients with advanced non-small-cell lung cancer in China.
Am J Cancer Res. 2015; 5(10):3270-3275.
2. Ozyurek BA, Ozdemirel TS, Ozden SB, Erdoğan Y, Ozmen O, Kaplan B, Kaplan T. Does
advanced lung inflammation index (ALI) have prognostic significance in metastatic
non-small cell lung cancer? Clin Respir J. 2018; 12(6):2013-2019.
3. Wang J, Chen J, Guo Y, Wang B, Chu H. Strategies targeting angiogenesis in advanced
non-small cell lung cancer. Oncotarget. 2017; 8(32):53854-53872.
4. Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic
strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015; 4(5):515-23.
5. Prevarskaya N, Skryma R, Shuba Y. Ion channels and the hallmarks of cancer. Trends
Mol Med. 2010; 16(3):107-21.
6. Munaron L. Intracellular calcium, endothelial cells and angiogenesis. Recent Pat
Anticancer Drug Discov. 2006; 1(1):105-19.
7. Bödding M. TRP proteins and cancer. Cell Signal. 2007; 19(3):617-24.
8. Azimi I, Milevskiy MJG, Kaemmerer E, Turner D, Yapa KTDS, Brown MA, Thompson EW,
Roberts-Thomson SJ, Monteith GR. TRPC1 is a differential regulator of hypoxia-mediated
events and Akt signalling in PTEN-deficient breast cancer cells. J Cell Sci. 2017;
130(14):2292-2305.
9. Weber LV, Al-Refae K, Wolk G, Bonatz G, Altmuller J, Becker C, Gisselmann G, Hatt
H. Expression and functionality of TRPV1 in breast cancer cells. Breast Cancer. 2016;
8:243–252.
10. Hope JM, Greenlee JD, King MR. Mechanosensitive Ion Channels: TRPV4 and P2X7 in
Disseminating Cancer Cells. Cancer J. 2018; 24(2):84-92.
11. Yang LL, Liu BC, Lu XY, Yan Y, Zhai YJ, Bao Q, Doetsch PW, Deng X, Thai TL, Alli
AA, Eaton DC, Shen BZ, Ma HP. Inhibition of TRPC6 reduces non-small cell lung cancer
cell proliferation and invasion. Oncotarget. 2017; 8(3):5123-5134.
12. Li X, Zhang Q, Fan K, Li B, Li H, Qi H, Guo J, Cao Y, Sun H. Overexpression of
TRPV3 Correlates with Tumor Progression in Non-Small Cell Lung Cancer. Int J Mol Sci.
2016; 17(4):437.
13. Liu Y, Qi H, E M, Shi P, Zhang Q, Li S, Wang Y, Cao Y, Chen Y, Ba L, Gao J, Huang
W, Sun H. Transient receptor potential vanilloid-3 (TRPV3) activation plays a central
role in cardiac fibrosis induced by pressure overload in rats via TGF-β1 pathway.
Naunyn Schmiedebergs Arch Pharmacol. 2018; 391(2): 131-143.
14. Aijima R, Wang B, Takao T, Mihara H, Kashio M, Ohsaki Y, Zhang JQ, Mizuno A, Suzuki
M, Yamashita Y, Masuko S, Goto M, Tominaga M, Kido MA. The thermosensitive TRPV3 channel
contributes to rapid wound healing in oral epithelia. FASEB J. 2015; 29(1):182–192.
15. Zhang Q, Cao Y, Luo Q, Wang P, Shi P, Song C, E M, Ren J, Fu B, Sun H. The transient
receptor potential vanilloid- 3 regulates hypoxia-mediated pulmonary artery smooth
muscle cells proliferation via PI3K/AKT signaling pathway. Cell Prolif. 2018; 51(3):e12436.
16. Abdou AG, Farag AGA, Hammam M, Taie DM, Abdelaziz RA. Immunohistochemical expression
HIF1α in chronic plaque psoriasis, an association with angiogenesis and proliferation.
J Immunoassay Immunochem. 2018; 39(3):249-262.
17. Kuppusamy B. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int
J Cancer. 2016; 138(5):1058-1066.
18. Azimi I. The interplay between HIF-1 and calcium signalling in cancer. Int J Biochem
Cell Biol. 2018; 97:73-77.
19. Hui AS, Bauer AL, Striet JB, Schnell PO, Czyzyk-Krzeska MF. Calcium signaling
stimulates translation of HIF-alpha during hypoxia. FASEB J. 2006; 20(3):466-75.
20. Zhu Y, Pan Q, Meng H, Jiang Y, Mao A, Wang T, Hua D, Yao X, Jin J, Ma X. Enhancement
of vascular endothelial growth factor release in long-term drug-treated breast cancer
via transient receptor potential channel 5-Ca(2+)-hypoxia-inducible factor 1α pathway.
Pharmacol Res. 2015; 93:36-42.
21. Lu H, Chen I, Shimoda LA, Park Y, Zhang C, Tran L, Zhang H, Semenza GL. Chemotherapy-Induced
Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment. Cell Rep. 2017; 18(8):1946-1957.
22. Li X, Wang X, Ye H, Peng A, Chen L. Barbigerone, an isoflavone, inhibits tumor
angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2
signaling pathways. Cancer Chemother Pharmacol. 2012; 70(3):425-37.
23. Cheng HW, James AF, Foster RR, Hancox JC, Bates DO. VEGF activates receptor-operated
cation channels in human microvascular endothelial cells. Arterioscler Thromb Vasc
Biol. 2006; 26(8):1768-1776.
24. Ge R, Tai Y, Sun Y, Zhou K, Yang S, Cheng T, Zou Q, Shen F, Wang Y. Critical role
of TRPC6 channels in VEGF-mediated angiogenesis. Cancer Lett. 2009; 283(1):43-51.
25. Kwan HY, Huang Y, Yao X. TRP channels in endothelial function and dysfunction.
Biochim Biophys Acta. 2007; 1772(8):907-914.
26. LJ, Ju HQ, Liu GP, Tian T, Ma GL, Lu YX, Liu ZX, Pan RL, Li RH, Piao HL, Marks
JR, Yang LJ, Yan Q, Wang W, Shao J, Zhou Y, Zhou T, Lin A. LncRNA CamK-A Regulates
Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling. Mol Cell. 2018; 72(1):71-83.
27. González A, Sáez CA, Morales B, Moenne A. Copper-induced activation of TRP channels
promotes extracellular calcium entry and activation of CaMK, PKA, PKC, PKG and CBLPK
leading to increased expression of antioxidant enzymes in Ectocarpus siliculosus.
Plant Physiol Biochem. 2018; 126:106-116.
28. Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini
AL, Mir O, Villanueva C, Barthélémy P. Angiogenesis and tumor microenvironment: bevacizumab
in the breast cancer model. Target Oncol. 2015; 10(2):189-98.
29. Isobe T, Aoyagi K, Koufuji K, Shirouzu K, Kawahara A, Taira T and Kage M. Clinicopathological
significance of hypoxia-inducible factor-1 alpha (HIF-1alpha) expression in gastric
cancer. Int J Clin Oncol. 2013; 18(2): 293-304.
30. Du H, Shi H, Chen D, Zhou Y, Che G. Cross-talk between endothelial and tumor cells
via basic fibroblast growth factor and vascular endothelial growth factor signaling
promotes lung cancer growth and angiogenesis. Oncol Lett. 2015; 9(3): 1089–1094.
31. Jour G, Ivan D, Aung PP. Angiogenesis in melanoma: an update with a focus on current
targeted therapies. J Clin Pathol. 2016; 69(6):472–483.
32. Ni X, Yu H, Wang S, Zhang C, Shen S. Astaxanthin inhibits PC- 3 xeno-graft prostate
tumor growth in nude mice. Mar Drugs. 2017; 15(3):66.
33. Li D, Huang Y, Dai M, Zhao X, Du Q, Dong F, Wang L, Huo R, Zhang W, Xu X, Tong
D. Transmissible gastroenteritis virus infection induces cell cycle arrest at S and
G2/M phases via p53-dependent pathway. Virus Res. 2013; 178(2):241-251.
34. Joshaghani HR, Jafari SM, Aghaei M, Panjehpour M, Abedi H. A3 adenosine receptor
agonist induce G1 cell cycle arrest via Cyclin D and cyclin- dependent kinase 4 pathways
in OVCAR- 3 and Caov- 4 cell lines. J Cancer Res Ther. 2017; 13(1):107-112.
35. Li M, Ouyang L, Zheng Z, Xiang D1, Ti A, Li L, Dan Y, Yu C, Li W. E3 ubiquitin
ligase FBW7α inhibits cholangiocarcinoma cell proliferation by downregulating c- Myc
and cyclin E. Oncol Rep. 2017; 37:1627-1636.
36. Ventura C, Núñez M, Gaido V, Pontillo C, Miret N, Randi A, Cocca C. Hexachlorobenzene
alters cell cycle by regulating p27-cyclin E-CDK2 and c-Src-p27 protein complexes.
Toxicol Lett. 2017; 270:72-79.